The BioMelbourne Network presents – Partnering Through the Healthcare Product Life-cycle
Supported by Swinburne University of Technology and the ARC Training Centre in Biodevices at Swinburne
The challenges of taking an idea to market in the healthcare sector requires a well planned and executed partnering strategy to deliver impact and outcomes. New approaches to deal making, collaboration and engagement are providing significant productivity and efficiency gains for biotech and medtech companies.
At this event our speakers will provide insights from start-up, academia and listed-biotech perspectives with a focus on approaches to partnering, collaborations and the role of networks in the development and commercialisation of healthcare products. The discussion will encompass multinational and local strategic partnerships, new business models and will be supported by the presentation of specific case studies, recent milestones and current projects.
Date: Wednesday 10th August, 2016
Time: Registration from 7:15am for a 7.30am breakfast networking followed by presentations and discussion from 8.00am – 9:00am
Address: The Royal Society of Victoria, 8 La Trobe St, Melbourne VIC 3000
Members – $65
Non-Members – $130
(Prices include GST)
To check if your organisation is a member click here
About our Speakers:
Jackie Fairley has more than 25 years of operational experience in the pharmaceutical and biotechnology industries with companies including CSL and Faulding (now Hospira/Pfizer) and most recently as CEO of ASX listed Starpharma Holdings (SPH).
Under her leadership the Company has advanced into ASX300, attracted significant new investment from global funds and developed several new and valuable commercial products based on Starpharma’s proprietary polymer technology. These include Dual Protect® the world’s first antiviral condom marketed by Ansell, VivaGel® for Bacterial Vaginosis (now approved in Europe) and DEP™ docetaxel and improved version of the leading cancer drug Taxotere. In her time as CEO Starpharma has also signed numerous strategically important commercial deals with leading companies including AstraZeneca, GSK, Lilly, Okamoto, Ansell, Aspen and Adama. The company has also raised >A$75m and significantly strengthened its institutional shareholder base attracting investment from major global funds including Prudential (M&G) and Fidelity.
In addition to her executive role Jackie also serves on the Board of the Melbourne Business School, and in 2014 was appointed to the Commonwealth Science Council chaired by the Prime Minister. She also sits on the Investment Committee of Mark Carnegie’s Innovation Fund. Her previous appointments include the Victorian Economic Review Panel, the Federal Government’s Pharmaceutical Industry Working Group, the Biotechnology Advisory Group and the Victorian Innovation Economy Advisory Board Chaired by the Premier.
Sally McArthur is the Director of the Innovation Precinct at Swinburne University of Technology. The precinct is a whole of university initiative focused on technology innovation and entrepreneurship through collaboration between students, staff, mentors, industry, strategic partners.
As an academic in Biomedical and Materials Engineering Sally has obtained approximately $16M in funding, including the $1.8M ARC Industrial Transformational Training Centre in Biodevices launched at Swinburne in March 2015. The centre links industry and academia to create a new generation of entrepreneurial, innovative and internationally connected graduates capable of driving the medical and manufacturing sectors forward.
Sally’s personal research couples materials, surface engineering, physical science, analytical chemistry and biochemistry. Her research spans medical, environmental, food and manufacturing technology sectors. Sally’s group hosts the Australian National Fabrication Facility Victoria (ANFF-Vic) Biointerface Engineering Hub, an open access facility for academic and industry researchers supporting the connection of biology with technology.
Jacqueline Savage, Founder and Director of MedCorp Technologies
Winner of the BioMelbourne Network 2016 Emerging Women in Leadership Award
Jacqueline Savage is the Founder of MedCorp Technologies, a medical device company developing wearable technologies for the healthcare industry.
As a young Australian product design engineer she is passionate and dedicated to improving healthcare through innovation. Jacqueline believes strongly in importance of the design process
in the development of medical devices, that a product is not just finding a solution to a problem, but also improving the end user’s experience.
After obtaining a Bachelor of Engineering (Product Design), specialising in Biomedical Engineering, Jacqueline has used her diverse range of skills to develop products from concept through to manufacture and global distribution. Voted Top 100 Global Engineering Innovations of 2014 (Create the Future, NASA Tech Briefs) and a finalist in last year’s 2015 Med Tech’s Got Talent competition, Jacqueline has received numerous industry acknowledgements and awards for her innovative approach to enabling remote healthcare.
When looking at Jacqueline’s CV you cannot help but be impressed by her academic successes as well as the depth and breadth of the external recognition.
Notably, Jacqueline has used her personal experience of surviving cancer to come up with the idea behind her business. She backs herself and importantly is passionate about converting her ideas to reality and doing that in a highly creative and innovative way.